$NBY A Masked Resurgence Recently, a litany of institutions have been reinstating mask mandates amidst a summer surge of Covid cases due to the Eris variant spread. These mask mandates may be a major catalyst for mask manufacturers. One of the mask manufacturers that stand to benefit from these mandates is NovaBay Pharmaceu
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.1634 USD
−7.21 M USD
9.78 M USD
5.82 M
About NovaBay Pharmaceuticals, Inc.
Sector
Industry
CEO
Justin M. Hall
Website
Headquarters
Emeryville
Founded
2000
FIGI
BBG000PVPJT3
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
NBY effective against Monkeypox ! 20X Upside Analyst Rating!!!NovaBay Pharmaceuticals, Inc. (NBY) owns Avenova, which is EPA listed as an effective disinfectant for monkeypox.
On 5/20/2022 Ascendiant Capital Markets brokerage set a price target of $4.00 for NovaBay Pharmaceuticals, Inc. (NBY).
The stock is now only 0.20usd.
Before the pandemic news, on thei
$NBY Novabay Pharma Rallies on Compliance NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
$NBY The weekly chart is Absolutely Gruesome!
The Longterm Downtrend appears to be closing, bottomed in May, double bottom is in and a Golden Cross is very close on the daily chart. Shallow Uptrend is in play, we should hopefully see some strong action coming into May 2021.
Hopefully those holding longterm should get some relief. Swing Traders
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of NBY is 0.6001 USD — it has decreased by −2.50% in the past 24 hours. Watch NovaBay Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange NovaBay Pharmaceuticals, Inc. stocks are traded under the ticker NBY.
NBY stock has risen by 14.71% compared to the previous week, the month change is a −5.65% fall, over the last year NovaBay Pharmaceuticals, Inc. has showed a −79.54% decrease.
NBY stock is 7.02% volatile and has beta coefficient of 1.68. Track NovaBay Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is NovaBay Pharmaceuticals, Inc. there?
Today NovaBay Pharmaceuticals, Inc. has the market capitalization of 3.49 M, it has increased by 17.98% over the last week.
Yes, you can track NovaBay Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NovaBay Pharmaceuticals, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
NBY earnings for the last quarter are 4.69 USD per share, whereas the estimation was −0.24 USD resulting in a 2.05 K% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about NovaBay Pharmaceuticals, Inc. earnings.
NovaBay Pharmaceuticals, Inc. revenue for the last quarter amounts to 2.31 M USD, despite the estimated figure of 2.50 M USD. In the next quarter, revenue is expected to reach 3.00 M USD.
NBY net income for the last quarter is −1.32 M USD, while the quarter before that showed −1.21 M USD of net income which accounts for −9.16% change. Track more NovaBay Pharmaceuticals, Inc. financial stats to get the full picture.
No, NBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 14 employees. See our rating of the largest employees — is NovaBay Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovaBay Pharmaceuticals, Inc. EBITDA is −4.85 M USD, and current EBITDA margin is −46.96%. See more stats in NovaBay Pharmaceuticals, Inc. financial statements.
Like other stocks, NBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovaBay Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NovaBay Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NovaBay Pharmaceuticals, Inc. stock shows the sell signal. See more of NovaBay Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.